Search 

Baxter Ventures is the strategic venture arm of Baxter International Inc. that was formed in 2011 and is based in Deerfield, Illinois. The firm is currently making equity investments out of a $200 Million fund with allocations generally falling in the $3-$5 million range. The firm is looking in invest in companies who have previously or are currently in the process of securing investment from other institutional investors. The firm is willing to look globally for investment opportunities and plans to make approximately 2 new investments over the next 6-9 months.

Bionic Vision Technologies is the commercial entity which holds license to the patents around technology developed by Bionic Vision Australia.

Bionic Vision Australia brings together Australia’s leading experts in medical bionics to develop a bionic eye to restore vision to people with retinitis pigmentosa and age-related macular degeneration.  A prototype device has been successfully implanted into three patients for two years demonstrating outstanding safety and efficacy. 

Our capabilities which  differentiate us from competitors include:

1. Novel surgical techniques providing greater safety and stability od wide view devices

2. World leading, pioneering vision processing software

3. Unique arrangement and stimulation strategies of the electrodes

4. Unique diamond electrode encapsulation for the high acuity device

5. World leading psychophysics laboratory for assessing functionality of the devices

6. Unprecedented expertise and proven track record in preclinical studies

Our development portfolio consists of  wide view devices which aim to increase mobility and independence of patients and a high acuity device which will allow patients the ability to read large letters and recognise faces

BioScience Managers is a venture capital life science investment firm headquartered in Melbourne, Australia. The group makes equity investments from $3M-5M and anticipates about 6 new investments this year. BioScience Managers invests globally. 

BioScience Managers will invest in companies across the life science space, including therapeutics, diagnostics and medical technology. The group does not invest in service providers. BioScience Managers considers all subsectors and indications, including orphan indications. The group will consider technology either in or prepared for human clinical trials and is open to all classes of devices. BioScience Managers seeks investments in novel technology and is not looking to gain share of an existing market. 

Regeneration Through Innovation

Celling Biosciences is dedicated to researching and developing the future of healing through regenerative medicine and the clinical use of autologous regenerative cells to facilitate the body’s capacity to heal itself. Through our patented Celling therapies and our Institutes of Regenerative Medicine, Celling Biosciences is moving the science of healing forward and redefining the global medical landscape.

Chempetitive Group is an integrated marketing communications agency focused exclusively on the life sciences. We work with biotech, medical device, pharmaceutical, chemical and tools/instrumentation companies of all sizes that around the globe. We develop winning strategies and campaigns that build brands and generate revenues. We love science. We understand science. And, we know how to effectively reach the scientific, clinical, medical and business communities that matter. 

Long live science. 

Visit us in San Diego, San Francisco, Chicago, Boston or Cambridge UK. 

Find out about us at http://www.chempetitive.com